Identifying Associations between Maternal Medication Use and Birth Defects Using a Case-Population Approach: An Exploratory Study on Signal Detection
Purchase on Springer.com
$49.95 / €39.95 / £34.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
The effects of many drugs on the unborn child are unknown. In a case-population design, drug exposure of cases is compared with that of a source population; this kind of study can be useful for generating signals.
To see whether a comparison of drug use rates from the birth defect registry EUROCAT NNL (cases) with prescription rates from a population-based prescription database, the IADB (population), could be used to detect signals of teratogenic risk of drugs.
We defined 3,212 cases from the EUROCAT NNL database, a population-based birth defect registry in the Northern Netherlands and 29,223 population controls from the IADB, a prescription database with data from community pharmacies in the same geographical area, born between 1998 and 2008. We classified the malformations of the 3,212 cases into several malformation groups according to organ system (based on the International Classification of Diseases codes and the EUROCAT guidelines). If a child had multiple malformations in several organ systems (n = 253, 7.9 %), he/she was counted in all the categories represented. For several groups of malformations we calculated rate ratios (RR) and 95 % confidence intervals for drugs acting on the central nervous system and for drugs considered to be safe for use in pregnancy. The RRs were based on first-trimester drug use rates from the cases in the EUROCAT NNL database and prescription rates from the population controls in the IADB.
For drugs acting on the central nervous system we found significantly increased RRs for the anti-epileptic drug valproic acid and for some selective serotonin reuptake inhibitors. For drugs considered to be safe only the anti-hypertensive methyldopa showed significantly increased RRs.
We show that a case-population study is a suitable method for detecting signals of possible teratogenicity, provided that the teratogenic effects and the drugs under study are as specific as possible and the drugs are widely used.
- Sadler TW. Langman’s medical embryology. 10th ed. Baltimore: Lippincott Williams and Wilkins; 2006.
- Andrade SE, Gurwitz JH, Davis RL, et al. Prescription drug use in pregnancy. Am J Obstet Gynecol. 2004;191(2):398–407. CrossRef
- Olesen C, Sorensen HT, de Jong-van den Berg LTW, et al. Prescribing during pregnancy and lactation with reference to the Swedish classification system: a population-based study among Danish women. Acta Obstet Gynecol Scand. 1999;78(8):686–92. CrossRef
- Olesen C, Steffensen FH, Niesen GL, et al. Drug use in first pregnancy and lactation: a population-based survey among Danish women: the EUROMAP group. Eur J Clin Pharmacol. 1999;55(2):139–44. CrossRef
- Buhimschi CS, Weiner CP. Medications in pregnancy and lactation: part 1. Teratology. Obstet Gynecol. 2009;113(1):166–88.
- Buhimschi CS, Weiner CP. Medications in pregnancy and lactation: part 2. Drugs with minimal or unknown human teratogenic effect. Obstet Gynecol. 2009;113(2 Pt 1):417–32.
- Bakker MK, Jentink J, Froom F, et al. Drug prescription patterns before, during and after pregnancy for chronic, occasional and pregnancy-related drugs in the Netherlands. BJOG. 2006;113(5):559–68. CrossRef
- Etwel FA, Rieder MJ, Bend JR, et al. A surveillance method for the early identification of idiosyncratic adverse drug reactions. Drug Saf. 2008;31(2):169–80. CrossRef
- Van der Klauw MM, Goudsmit R, Halie MR, et al. A population-based case-cohort study of drug-associated agranulocytosis. Arch Intern Med. 1999;159(22):369–74. CrossRef
- Capellà D, Pedrós C, Vidal X, et al. Case-population studies in pharmacoepidemiology. Drug Saf. 2002;25(1):7–19. CrossRef
- Théophile H, Laporte JR, Moore N, et al. The case-population study design: an analysis of its application in pharmacovigilance. Drug Saf. 2011;34(10):861–8. CrossRef
- Greenlees R, Neville A, Addor MC, et al. Paper 6: EUROCAT Member Registries: organization and activities. Birth defects research (part A): clinical and molecular. Teratology. 2011;91:51–100.
- World Health Organization. International statistical classification of diseases and related health problems. 10th revision (ICD-10). Geneva: WHO, 1992.
- World Health Organization. Collaborating Centre for Drugs Statistics Methodology. ATC/DDD Index. 2012. http://www.whocc.no/atc_ddd_index/. Accessed 30 Aug 2012.
- Bakker MK, de Walle HEK, Dequito A, et al. Selection of controls in case-control studies on maternal medication use and risk of birth defects. Birth Defects Res A Clin Mol Teratol. 2007;79(9):652–6. CrossRef
- Eurocat guidelines. http://www.eurocat-network.eu/ à about us à data collection. Accessed 12 March 2013.
- Schirm E, Tobi H, de Jong-van den Berg LTW. Identifying parents in pharmacy data: a tool for the continuous monitoring of drug exposure to unborn children. J Clin Epidemiol. 2004;57(7):737–41. CrossRef
- Eadie MJ. Antiepileptic drugs as human teratogens. Expert Opin Drug Saf. 2008;7(2):195–210. CrossRef
- Jentink J, Loane MA, Dolk H, et al. Valproic acid monotherapy in pregnancy and major congenital malformations. N Engl J Med. 2010;362(23):2185–93. CrossRef
- Jentink J, Dolk H, Loane MA, et al. Intrauterine carbamazepine exposure and specific congenital malformations. BMJ. 2010;341:c6581. CrossRef
- Wyszynski DF, Nambisan M, Surve T, et al. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology. 2005;64(2):961–5. CrossRef
- Werler MM, Ahrens KA, Bosco JL, et al. Use of antiepileptic medications in pregnancy in relation to risks of birth defects. Ann Epidemiol. 2011;21(11):842–50. CrossRef
- Dolk H, Jenktink J, Loane MA, et al. Does lamotrigine use in pregnancy increase orofacial cleft risk relative to other malformations? Neurology. 2008;71(10):714–22. CrossRef
- Vajda FJE, Graham JE, Hitchcock AA, et al. Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register. Seizure. 2010;19(9):558–61. CrossRef
- http://www.tga.gov.au/hp/medicines-pregnancy.htm. Accessed 9 Feb 2012.
- Hill AB. The environment and disease association or causation. Proc R Soc Med. 1965;58:295–300.
- Meyboom RH, Egberts AC, Edwards IR, et al. Principles of signal detection in pharmacovigilance. Drug Saf. 1997;16(6):355–65. CrossRef
- Meyboom RH, Lindquist M, Egberts AC, et al. Signal selection and follow-up in pharmacovigilance. Drug Saf. 2002;25(6):459–65. CrossRef
- Kozma C. Valproic acid embryopathy: report of two siblings with further expansion of the phenotypic abnormalities and a review of the literature. Am J Med Genet. 2001;98(2):168–75. CrossRef
- Bakker MK, de Walle HEK, Wilffert B, et al. Fluoxetine and infantile hypertrophic pylorus stenosis, a signal from a birth defects case-control monitoring system. Pharmacoepidemiol Drug Saf. 2010;19(8):808–13. CrossRef
- Colvin L, Slack-Smith L, Stanley FJ, et al. Dispensing patterns and pregnancy outcomes for women dispensed selective serotonin reuptake inhibitors in pregnancy. Birth Defects Res A Clin Mol Teratol. 2011;91(3):142–52. CrossRef
- Malm H, Artama M, Gissler M, et al. Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstet Gynecol. 2011;118(1):111–20. CrossRef
- Pedersen LH, Henriksen TB, Vestergaard M, et al. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ. 2009;339:b3569. CrossRef
- Stevenson DA, Mineau G, Kerber RA, et al. Familial predisposition to developmental dysplasia of the hip. J Pediatr Orthop. 2009;29(5):463–6. CrossRef
- Louik C, Lin AE, Werler MM, et al. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med. 2007;356(26):2675–83. CrossRef
- Reis M, Källén B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med. 2010;40(10):1723–33. CrossRef
- Bakker MK, Kerstjens-Frederikse WS, Buys CH, et al. First trimester use of paroxetine and congenital heart defects, a population-based case-control study. Birth Defects Res A Clin Mol Teratol. 2010;88(2):94–100.
- Scialli AR. Paroxetine exposure during pregnancy and cardiac malformations. Birth Defects Res A Clin Mol Teratol. 2010;88:175–7.
- Lindheimer MD. Hypertension in pregnancy. Hypertension. 1993;22(1):127–37. CrossRef
- Lennestal R, Otterblad Olausson PO, Källén B, et al. Maternal use of antihypertensive drugs in early pregnancy and delivery outcome, notably the presence of heart defects in the infants. Eur J Clin Pharmacol. 2009;65(6):615–25. CrossRef
- Caton AR, Bell EM, Druschel CM, et al. Antihypertensive medication use during pregnancy and the risk of cardiovascular malformations. Hypertension. 2009;54(1):63–70. CrossRef
- Li DK, Yang C, Andrade S, et al. Maternal exposure to ACE-inhibitors in the first trimester and risk of malformations in offspring: a retrospective cohort study. BMJ. 2011;343:d5931. CrossRef
- Mitchell AA. Fetal risk from ACE inhibitors in the first trimester. BMJ. 2011;343:d6667. CrossRef
- De Jong-van den Berg LTW, Waardenburg CM, Haaijer-Ruskamp FM, et al. Drug use in pregnancy: a comparative appraisal of data collecting methods. Eur J Clin Pharmacol. 1993;45(1):9–14.
- Olesen C, Søndergaard C, Thrane N, et al. Do pregnant women report use of dispensed medication. Epidemiology. 2001;12(5):497–501. CrossRef
- EUROCAT NNL. http://www.rug.nl/umcg/faculteit/disciplinegroepen/medischegenetica/eurocat/Algemenecijferstabel123en4.pdf (in Dutch). Accessed 30 Aug 2012.
- Identifying Associations between Maternal Medication Use and Birth Defects Using a Case-Population Approach: An Exploratory Study on Signal Detection
Volume 36, Issue 11 , pp 1069-1078
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Author Affiliations
- 1. EUROCAT Registration Northern Netherlands, Department of Genetics, University Medical Center Groningen, PO Box 30.001, 9700 RB, Groningen, The Netherlands
- 3. University of Groningen, University Medical Center Groningen, Department of Genetics, Eurocat Registration Northern Netherlands, Groningen, The Netherlands
- 2. Unit of PharmacoEpidemiology and PharmacoEconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands